Clinical Commander

All dossiers
cardio.atrial_flutter.with-cardiogenic-shock.v1

Atrial flutter precipitating cardiogenic shock (AFL with RVR + low-output state)

cardiologyacuteadultacuteinpatienttransitionoutpatient
Start encounter →Print handoutPRODUCTION

Phase E variant of cardio.atrial_flutter.v1 — composite atrial flutter precipitating cardiogenic shock. Inherits AC + acute rate/rhythm management from parent; specializes for emergent synchronized DCCV at 100J biphasic (Class I per ACC/AHA 2024 PMID 38753446 — only intervention restoring atrial kick acutely), inotrope/pressor support (NE for MAP, dobutamine for low CI per SCAI 2022 PMID 35718438), AC bridge with heparin → DOAC, MCS escalation per DanGer Shock (PMID 38587234) for SCAI C+, and CTI ablation pathway (Class I per Calkins 2007 PMID 17572388) for typical AFL with recurrent decompensation. Critical clinical pearl: do NOT delay DCCV for TEE if hemodynamically unstable — give heparin bolus (60 U/kg IV) then proceed with CV per ACC/AHA 2024 Class I. Pre-existing HFrEF / severe MS / severe AS substrates have highest shock vulnerability; full-dose AVN blockade (BB or non-DHP CCB) AVOIDED given negative inotropy worsens hypoperfusion; esmolol or low-dose diltiazem only if EF preserved + BP recovered. GDMT initiation (ARNI + BB + MRA + SGLT2i per 2022 ACC/AHA HF) for HFrEF substrate begins once off inotropes ≥48 h. Lifelong AC indicated regardless of CHA2DS2-VASc given cardiomyopathy substrate; LAA occlusion (Watchman) considered if AC contraindicated long-term. Manifest pointer reuses cardio.atrial_flutter.v1 manifest. Design-brief pointer reuses parent. Status INTEGRATED until terminology + RxNav-validated drug codes are reconciled. Authored 2026-05-15 by shard-06-cardio-acute.

Entry points (4)

  • imaging
    Atrial flutter on monitor + SBP <90 mmHg + signs of hypoperfusion (cool extremities, lactate ≥2, oliguria, AMS) → SCAI B-C cardiogenic shock screen with emergent DCCV indication (ACC/AHA 2024 Class I PMID 38753446)
    aflutter_with_sbp_below_90
  • imaging
    New-onset AFL with RVR + acute pulmonary edema in patient with pre-existing HFrEF or critical valvular disease — composite emergency requiring emergent DCCV before pharmacologic rate control
    new_aflutter_with_acute_pulmonary_edema
  • history
    Known severe aortic stenosis or severe mitral stenosis with new AFL + acute decompensation (atrial kick essential to maintain stroke volume across stenotic valve)
    aflutter_in_severe_as_or_severe_ms_with_decompensation
  • symptom
    Syncope or pre-syncope in patient with AFL RVR + sustained hypotension — signals critical low-output state requiring ICU + DCCV
    syncope_with_aflutter_rvr_and_hypotension

Required inputs (15)

  • agerequired
    demographic • used at CONTEXT
    Elderly / frail patients have limited inotropic reserve; CHA2DS2-VASc; informs MCS candidacy + cardiothoracic surgery decision
  • sbprequired
    vital • used at RED_FLAGS
    SBP <90 with AFL = SCAI B-C shock; gates emergent synchronized DCCV (ACC/AHA 2024 Class I); MAP <65 triggers norepinephrine; serial trend after CV/inotrope
  • hrrequired
    vital • used at CONTEXT
    AFL RVR HR 130–180+ with conduction ratio 2:1 most common; HR target post-CV restoration sinus rhythm
  • spo2required
    vital • used at RED_FLAGS
    Hypoxemia from acute pulmonary edema; gates BiPAP / HFNC / intubation; pre-oxygenation critical given hemodynamic fragility for DCCV procedural sedation
  • lactaterequired
    lab • used at RED_FLAGS
    Lactate ≥2 mmol/L confirms tissue hypoperfusion → SCAI B-C; serial q1–2h tracks response to CV + inotrope; lactate clearance predicts survival
  • bnp_or_ntprobnprequired
    lab • used at INITIAL_WORKUP
    Elevated BNP / NT-proBNP confirms acute heart failure component; trend post-CV reflects atrial-kick restoration benefit
  • troponinrequired
    lab • used at INITIAL_WORKUP
    Troponin elevation indicates demand ischemia from RVR or concomitant ACS; gates acs_pathway routing if persistent rise
  • creatinine_egfrrequired
    lab • used at INITIAL_WORKUP
    AKI common in shock (cardiorenal); eGFR for DOAC dose; trend monitors end-organ response
  • bmp_mg_krequired
    lab • used at INITIAL_WORKUP
    K+ ≥4 and Mg ≥2 mandatory before DCCV (reduces post-CV arrhythmia risk); replete urgently
  • ecg_12_leadrequired
    imaging • used at INITIAL_WORKUP
    Confirm AFL morphology + conduction ratio; rule out STEMI mimic; baseline QTc before any AAD
  • echo_lv_valvular_functionrequired
    imaging • used at INITIAL_WORKUP
    Bedside echo: LVEF, valvular function (severe MS/AS where atrial kick is critical), pericardial effusion, RV function, LA size, thrombus screen — drives MCS decision and post-CV surveillance
  • tee_pre_cardioversion
    imaging • used at TREATMENT
    TEE if cardioversion delayed beyond 48 h without therapeutic AC OR if AFL duration uncertain — excludes LAA thrombus before CV; if hemodynamically unstable, do not delay CV for TEE — proceed with heparin bolus then CV (ACC/AHA 2024)
  • cha2ds2_vasc_factorsrequired
    history • used at RISK_STRATIFICATION
    CHA2DS2-VASc for AFL stroke risk; in shock context lifelong AC indicated regardless of score given cardiomyopathy substrate
  • bleeding_historyrequired
    history • used at RISK_STRATIFICATION
    HAS-BLED for AC bleed risk; informs heparin bridge + DOAC selection
  • pre_existing_lv_dysfunction_or_valvular_diseaserequired
    history • used at CONTEXT
    HFrEF / severe MS / severe AS / HCM substrate predicts shock vulnerability; gates anticipatory ICU admission + early MCS evaluation

12-phase flow (12)

  1. 1FRAME
    Atrial flutter precipitating cardiogenic shock — AFL RVR + loss of atrial kick + tachycardia-mediated cardiomyopathy → SCAI B-C low-output state, especially in HFrEF / severe valvular / elderly. Two parallel decisions: (1) restore atrial mechanical contribution via emergent DCCV (Class I per ACC/AHA 2024 PMID 38753446); (2) inotropic + vasopressor support for shock (NE for MAP, dobutamine for CI) per SCAI 2022 (PMID 35718438) + DanGer Shock (PMID 38587234)
    inputs: ecg_12_lead, echo_lv_valvular_function
    advance: AFL + shock confirmed; substrate identified
  2. 2ENTRY
    AFL on monitor + SBP <90 + hypoperfusion signs → emergent ICU + DCCV pathway; coordinate with cardiology + critical care
    inputs: age, spo2
    advance: engine entered + ICU activated
  3. 3CONTEXT
    Pre-existing LV dysfunction (HFrEF EF), valvular pathology (severe MS / AS), HCM, prior AC, CHA2DS2-VASc factors, bleeding history, prior cardioversion / ablation, AFL chronicity (paroxysmal vs persistent), comorbidity, code status
    inputs: hr, cha2ds2_vasc_factors, bleeding_history, pre_existing_lv_dysfunction_or_valvular_disease
    advance: context complete
  4. 4RED_FLAGS
    SBP <90 + lactate ≥2 + AMS / cool extremities = SCAI B-C → emergent synchronized DCCV at 100J biphasic (Class I per ACC/AHA 2024); refractory shock despite CV → MCS evaluation (Impella, IABP, VA-ECMO per SCAI/DanGer); acute pulmonary edema → BiPAP + emergent CV; failed DCCV at maximum energy → urgent EP for chemical CV with ibutilide if QTc safe + electrolytes repleted, else amiodarone load
    inputs: sbp, spo2, lactate
    actions: tachycardia, cardiogenic_shock
    advance: shock escalation triaged + CV pathway initiated
  5. 5INITIAL_WORKUP
    STAT 12-lead ECG + bedside echo (LV/RV/valvular/effusion) + troponin + BNP + BMP (K, Mg) + lactate + CBC + coags + ABG; replete K to ≥4 and Mg to ≥2 before DCCV
    inputs: ecg_12_lead, echo_lv_valvular_function, troponin, bnp_or_ntprobnp, creatinine_egfr, bmp_mg_k, lactate
    actions: acs_pathway, cardiogenic_shock, panel.cardiac, panel.renal
    advance: workup returned + electrolytes repleted + CV pre-conditions met
  6. 6BRANCHING_WORKUP
    TEE pre-CV if hemodynamics permit + AFL >48 h or unknown duration without prior therapeutic AC; if too unstable, proceed with heparin bolus then DCCV without TEE (ACC/AHA 2024); concomitant AF detection routes to cardio.afib.core.v1 for AC strategy alignment; if STEMI on ECG → acs_pathway primary culprit
    inputs: tee_pre_cardioversion
    actions: afib_new_onset
    advance: branch resolved + CV approach finalized
  7. 7DIFFERENTIAL
    AFL precipitating shock vs AFL incidental in pre-existing decompensated HF vs ACS with new AFL secondary to ischemia vs PE causing AFL + RV failure (route to cardio.atrial_flutter.with-pe.v1) vs septic shock with concomitant AFL
    advance: primary substrate identified
  8. 8RISK_STRATIFICATION
    SCAI shock stage (A-E) per Baran 2022 PMID 35718438; CHA2DS2-VASc for long-term AC; HAS-BLED for AC bleed risk; consider STS/SCAI for surgical candidacy if MS/AS substrate
    inputs: cha2ds2_vasc_factors, bleeding_history
    actions: calc.cha2ds2vasc, calc.has_bled, calc.ckd_epi_2021
    advance: SCAI stage + AC + bleed tier documented
  9. 9TREATMENT
    Emergent synchronized DCCV at 100J biphasic (Class I per ACC/AHA 2024 PMID 38753446 — only intervention restoring atrial kick acutely); norepinephrine 0.05–0.5 mcg/kg/min for MAP ≥65; dobutamine 2.5–10 mcg/kg/min for low CI (cautious — may worsen ischemia or arrhythmia); IV esmolol 25–100 mcg/kg/min OR diltiazem 5 mg IV CAUTIOUSLY if CV initially declined or as bridge — AVOID full-dose AVN blockade given hypoperfusion; AC: heparin 60 U/kg bolus + 12 U/kg/h infusion bridge to DOAC (apixaban 5 mg BID) once stable; long-term CTI ablation Class I if typical AFL + recurrent decompensation (Calkins 2007 PMID 17572388); GDMT initiation for underlying HFrEF — ARNI + BB + MRA + SGLT2i per 2022 HF guideline; emergent TEE delayed if hemodynamically unstable — proceed with heparin then CV
    inputs: sbp, creatinine_egfr, bmp_mg_k
    advance: CV delivered or chemical-CV pathway active + hemodynamic support stabilized + AC initiated
  10. 10DISPOSITION
    CICU mandatory; advanced HF / MCS service consultation if SCAI C+ or refractory shock; cardiothoracic surgery if MS/AS substrate; coordinate with EP for early ablation pathway
    advance: CICU bed + consults documented
  11. 11MONITORING
    Continuous telemetry; A-line + central line for tight hemodynamic management; serial lactate q1–2h until normalized; serial echo q24h to track LV recovery + atrial mechanical function; PTT q6h on heparin; daily K/Mg/BMP; daily ECG for AFL recurrence; QTc daily on AAD
    inputs: ecg_12_lead
    actions: panel.cardiac, panel.renal
    advance: monitoring orders documented + recovery trajectory tracked
  12. 12FOLLOWUP
    Cardiology + EP follow-up at week 1 + month 1; advanced HF follow-up if HFrEF; CTI ablation booked at 4–8 weeks if typical AFL + recurrent decompensation (Calkins 2007 PMID 17572388); valve replacement / repair if MS/AS substrate driving recurrence; cardiac rehab; lifelong AC per CHA2DS2-VASc + cardiomyopathy substrate
    advance: follow-up booked + ablation/valve pathway documented